Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial (OPT-BIRISK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03431142
Recruitment Status : Recruiting
First Posted : February 13, 2018
Last Update Posted : September 19, 2019
Information provided by (Responsible Party):
Han Yaling, Shenyang Northern Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : January 31, 2021